MCID: ATM011
MIFTS: 67

Autoimmune Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Autoimmune Hepatitis

MalaCards integrated aliases for Autoimmune Hepatitis:

Name: Autoimmune Hepatitis 39 12 77 54 60 38 15 17
Hepatitis, Autoimmune 45 74
Autoimmune Hepatitis with Centrilobular Necrosis 12
Autoimmune Chronic Active Hepatitis 12
Autoimmune Chronic Hepatitis 54
Chronic Autoimmune Hepatitis 60
Hepatitis Autoimmune 56
Aih 54

Characteristics:

Orphanet epidemiological data:

60
autoimmune hepatitis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Norway),1-5/10000 (Norway),1-9/1000000 (Sweden),1-5/10000 (New Zealand),1-9/1000000 (Spain),1-5/10000 (Spain),1-5/10000 (Sweden),1-9/1000000 (Israel),1-5/10000 (Israel),1-9/100000 (Denmark),1-5/10000 (Denmark),1-9/100000 (Singapore),1-9/100000; Age of onset: Adult;

Classifications:

Orphanet: 60  
Rare hepatic diseases


Summaries for Autoimmune Hepatitis

NIH Rare Diseases : 54 Autoimmune hepatitis is a disease in which the body�??s immune system attacks liver cells. This immune response causes inflammation of the liver, also called hepatitis. The disease can be quite serious and, if not treated, gets worse over time, leading to cirrhosis of the liver and/or liver failure. Autoimmune hepatitis likely results from a combination of autoimmunity, environmental triggers, and a genetic predisposition. It occurs more frequently in females. Treatment typically includes corticosteroids and medications that suppress the immune system. In severe cases, a liver transplant may be needed.

MalaCards based summary : Autoimmune Hepatitis, also known as hepatitis, autoimmune, is related to hepatitis and hepatitis a. An important gene associated with Autoimmune Hepatitis is SEPSECS (Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase), and among its related pathways/superpathways are Allograft rejection and Translocation of ZAP-70 to Immunological synapse. The drugs Prednisolone phosphate and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are increased circulating igg level and elevated hepatic transaminase

Disease Ontology : 12 An autoimmune disease of gastrointestinal tract that results in inflammation located in liver caused by the body's immune system attacking the liver cells.

Wikipedia : 77 Autoimmune hepatitis, formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver... more...

Related Diseases for Autoimmune Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Autoimmune Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 325)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.4 F2 GGT1 GPT KRT8 SEPSECS SLC17A5
2 hepatitis a 31.4 F2 GPT SEPSECS
3 infantile liver failure syndrome 1 30.8 F2 GPT SLC17A5
4 celiac disease 1 30.8 CTLA4 HLA-A HLA-DQB1
5 acute liver failure 30.7 F2 GPT SLC17A5
6 cholangitis 30.3 DLAT F2 GGT1 GPT HLA-DRB1
7 nonalcoholic steatohepatitis 30.2 F2 GPT SLC17A5
8 hepatitis b 30.2 CTLA4 F2 GGT1 GPT SLC17A5
9 hashimoto thyroiditis 30.2 AIRE CTLA4 FAS
10 multiple sclerosis 30.1 CTLA4 HLA-DQB1 HLA-DRB1 PDCD1
11 cryptogenic cirrhosis 30.1 F2 KRT8
12 pure red-cell aplasia 30.1 HLA-A HLA-DQB1 HLA-DRB1
13 fatty liver disease 30.1 FAS GGT1 SLC17A5
14 liver cirrhosis 30.0 F2 GGT1 GPT KRT8 SLC17A5
15 systemic lupus erythematosus 29.8 CTLA4 F2 FAS HLA-DQB1 HLA-DRB1 PDCD1
16 cholangitis, primary sclerosing 29.8 AIRE DLAT GGT1 GPT HLA-A SEPSECS
17 hepatic encephalopathy 29.7 F2 GPT SLC17A5
18 cholestasis 29.7 F2 GGT1 GPT
19 viral hepatitis 29.7 F2 FAS GGT1 GPT SEPSECS SLC17A5
20 hepatic coma 29.7 F2 GPT
21 vitiligo-associated multiple autoimmune disease susceptibility 1 29.6 AIRE CTLA4 PDCD1
22 diabetes mellitus 29.5 AIRE CTLA4 FAS HLA-A HLA-DQB1 HLA-DRB1
23 autoimmune disease 29.2 AIRE CTLA4 FAS HLA-DQB1 HLA-DRB1 PDCD1
24 liver disease 28.9 DLAT F2 FAS GGT1 GOLM1 GPT
25 amelogenesis imperfecta hypomaturation type 11.1
26 primary biliary cholangitis 10.7
27 biliary cirrhosis, primary, 1 10.7
28 primary biliary cirrhosis 10.7
29 hepatitis c 10.6
30 sclerosing cholangitis 10.6
31 limbic encephalitis with lgi1 antibodies 10.4 HLA-DQB1 HLA-DRB1
32 type 1 diabetes mellitus 12 10.4 CTLA4 HLA-DRB1
33 postherpetic neuralgia 10.4 HLA-A HLA-DRB1
34 narcolepsy 2 10.4 HLA-DQB1 HLA-DRB1
35 autoimmune polyglandular syndrome type 3 10.4 HLA-DQB1 HLA-DRB1
36 hepatocellular carcinoma 10.4
37 hypersomnia 10.4 HLA-DQB1 HLA-DRB1
38 metal allergy 10.4 HLA-DQB1 HLA-DRB1
39 paraquat poisoning 10.4 GPT SLC17A5
40 hepatitis c virus 10.4
41 lichen planopilaris 10.4 HLA-DQB1 HLA-DRB1
42 lupus erythematosus 10.4
43 pyridoxine deficiency 10.4 GPT SLC17A5
44 beryllium disease 10.4 HLA-DQB1 HLA-DRB1
45 recurrent respiratory papillomatosis 10.4 HLA-DQB1 HLA-DRB1
46 anca-associated vasculitis 10.4 CTLA4 HLA-DRB1
47 narcolepsy 1 10.4 HLA-DQB1 HLA-DRB1
48 hepatoportal sclerosis 10.4 F2 GPT
49 chronic beryllium disease 10.4 HLA-DQB1 HLA-DRB1
50 pars planitis 10.3 HLA-A HLA-DRB1

Graphical network of the top 20 diseases related to Autoimmune Hepatitis:



Diseases related to Autoimmune Hepatitis

Symptoms & Phenotypes for Autoimmune Hepatitis

Human phenotypes related to Autoimmune Hepatitis:

33 60 (show all 33)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 increased circulating igg level 33 obligate (100%) HP:0003237
2 elevated hepatic transaminase 60 33 hallmark (90%) Very frequent (99-80%) HP:0002910
3 antineutrophil antibody positivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0003453
4 smooth muscle antibody positivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0003262
5 antinuclear antibody positivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0003493
6 liver kidney microsome type 1 antibody positivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0030908
7 anti-liver cytosolic antigen type 1 antibody positivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0030909
8 depressivity 60 33 frequent (33%) Frequent (79-30%) HP:0000716
9 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
10 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
11 chronic fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012432
12 spider hemangioma 60 33 frequent (33%) Frequent (79-30%) HP:0012522
13 arthritis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001369
14 splenomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0001744
15 ascites 60 33 occasional (7.5%) Occasional (29-5%) HP:0001541
16 anxiety 60 33 occasional (7.5%) Occasional (29-5%) HP:0000739
17 vitiligo 60 33 occasional (7.5%) Occasional (29-5%) HP:0001045
18 thyroiditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100646
19 cirrhosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001394
20 jaundice 60 33 occasional (7.5%) Occasional (29-5%) HP:0000952
21 gastrointestinal hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0002239
22 acute hepatitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0200119
23 ulcerative colitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100279
24 glomerulonephritis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000099
25 increased total bilirubin 60 33 occasional (7.5%) Occasional (29-5%) HP:0003573
26 diffuse hepatic steatosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0006555
27 sclerosing cholangitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0030991
28 hepatocellular carcinoma 60 33 very rare (1%) Very rare (<4-1%) HP:0001402
29 fulminant hepatitis 60 33 very rare (1%) Very rare (<4-1%) HP:0004787
30 viral hepatitis 60 33 very rare (1%) Very rare (<4-1%) HP:0006562
31 inflammation of the large intestine 60 Occasional (29-5%)
32 increased igg level 60 Obligate (100%)
33 increased antibody level in blood 60 Obligate (100%)

MGI Mouse Phenotypes related to Autoimmune Hepatitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 AIRE CTLA4 CYP1A2 F2 FAS GGT1
2 liver/biliary system MP:0005370 9.76 AIRE CTLA4 CYP1A2 FAS GOLM1 HLA-DQB1
3 mortality/aging MP:0010768 9.73 AIRE CTLA4 CYP1A2 F2 FAS GGT1
4 respiratory system MP:0005388 9.17 AIRE CTLA4 CYP1A2 F2 FAS HLA-DQB1

Drugs & Therapeutics for Autoimmune Hepatitis

Drugs for Autoimmune Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
5
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7
Azathioprine Approved Phase 4,Phase 2,Not Applicable 446-86-6 2265
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Not Applicable
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1,Phase 2
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
18 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
20 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
22 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
24 Prednisolone acetate Phase 4,Phase 3,Not Applicable
25 Methylprednisolone Acetate Phase 4,Phase 3,Not Applicable
26 Antiemetics Phase 4,Phase 3
27 Liver Extracts Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Protective Agents Phase 4,Phase 3
30 Neuroprotective Agents Phase 4,Phase 3
31 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Chloroquine diphosphate Phase 4 50-63-5
33 Anthelmintics Phase 4
34 Antimetabolites Phase 4,Phase 2
35 Antimalarials Phase 4
36 Antimetabolites, Antineoplastic Phase 4,Phase 2
37 Antiparasitic Agents Phase 4,Not Applicable
38 Antiprotozoal Agents Phase 4,Not Applicable
39 Anti-Bacterial Agents Phase 4,Not Applicable
40 Antibiotics, Antitubercular Phase 4,Not Applicable
41 Antitubercular Agents Phase 4
42
Miconazole Approved, Investigational, Vet_approved Phase 3,Not Applicable 22916-47-8 4189
43
Budesonide Approved Phase 2, Phase 3,Not Applicable 51333-22-3 5281004 63006
44 Calcineurin Inhibitors Phase 3,Phase 2
45 Cyclosporins Phase 3
46 Antifungal Agents Phase 3,Not Applicable
47 Dermatologic Agents Phase 3
48 Anti-Asthmatic Agents Phase 2, Phase 3,Not Applicable
49 Bronchodilator Agents Phase 2, Phase 3,Not Applicable
50 Respiratory System Agents Phase 2, Phase 3,Not Applicable

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
2 CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
3 Mycophenolate vs Azathioprin in Autoimmune Hepatitis Completed NCT00687180 Phase 4 Treatment with mycophenolat mofetil;Treatment with azathioprin
4 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
5 Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis Recruiting NCT02900443 Phase 4 Mycophenolate mofetil;Azathioprine
6 Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis Unknown status NCT01170351 Phase 3 Cyclosporine-A
7 Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Completed NCT00838214 Phase 2, Phase 3 budesonide;prednisone
8 ADCC Mediated B-Cell dEpletion and BAFF-R Blockade Recruiting NCT03217422 Phase 2, Phase 3
9 Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis Withdrawn NCT02878863 Phase 3 Paeoniflorin + phosphatidylcholine or silymarin;Phosphatidylcholine or silymarin
10 Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis Unknown status NCT02704338 Phase 1, Phase 2
11 Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Unknown status NCT01661842 Phase 1, Phase 2
12 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
13 LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis Completed NCT00608894 Phase 2 LCP-Tacro (tacrolimus);Azathioprine
14 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
15 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
16 A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH Recruiting NCT02997878 Phase 1, Phase 2
17 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
18 Liver Test Study of Using JKB-122 in AIH Patients Active, not recruiting NCT02556372 Phase 2 JKB-122
19 Phase II AutoImmune Hepatitis Withdrawn NCT03593460 Phase 2 Synthetic PreImplantation Factor
20 sPIF CLINICAL STUDY PROTOCOL FOR AUTOIMMUNE HEPATITIS Completed NCT02239562 Phase 1 sPIF;Placebo
21 Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Completed NCT01088607 Phase 1 ursodeoxycholic acid (UDCA)
22 Volatile Organic Compounds (VOCs) and Liver Diseases Unknown status NCT01279356
23 Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis Unknown status NCT00160940
24 Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis Completed NCT01655121 Not Applicable
25 Transient Elastography in Autoimmune Hepatitis Completed NCT01905254 Not Applicable
26 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
27 European Safety Registry in Ulcerative Colitis (P04808) Completed NCT00705484 Standard Therapy
28 Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients Completed NCT02248545
29 De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation Recruiting NCT02056054
30 Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis Recruiting NCT03711669
31 Study of the Clinical Features of Autoimmune Hepatitis Recruiting NCT02994537
32 The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis Recruiting NCT02050646 Not Applicable
33 Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Recruiting NCT02936596 Not Applicable Ursodeoxycholic acid combination of immunosuppressive agents;Ursodeoxycholic Acid
34 Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis Recruiting NCT02874586 Not Applicable
35 Swiss Autoimmune Hepatitis Cohort Study Recruiting NCT03146884
36 Canadian Network for Autoimmune Liver Disease Recruiting NCT03569826
37 Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI Recruiting NCT03198104
38 MRI Based Biomarkers in Pediatric Autoimmune Liver Disease Recruiting NCT03175471
39 MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease Recruiting NCT03178630
40 "Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children" Recruiting NCT03069976 Not Applicable Metronidazole
41 The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis Recruiting NCT02461979 Not Applicable
42 Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Recruiting NCT03941184
43 Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis Active, not recruiting NCT02950077 Not Applicable
44 SRL (Sirolimus) Withdrawal Active, not recruiting NCT02062944 Not Applicable Sirolimus
45 Repeatability and Reproducibility of Multiparametric MRI Active, not recruiting NCT03743272
46 Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease Enrolling by invitation NCT03842254 Early Phase 1 Erythropoietin
47 EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2) Not yet recruiting NCT03444805
48 Autoimmune Hepatitis Study Terminated NCT00286663
49 Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis Withdrawn NCT00587119 Not Applicable Budesonide

Search NIH Clinical Center for Autoimmune Hepatitis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Autoimmune Hepatitis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: hepatitis, autoimmune

Genetic Tests for Autoimmune Hepatitis

Anatomical Context for Autoimmune Hepatitis

MalaCards organs/tissues related to Autoimmune Hepatitis:

42
Liver, T Cells, Thyroid, Testes, Kidney, Bone, Smooth Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Autoimmune Hepatitis:

20
Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Autoimmune Hepatitis:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Autoimmune Hepatitis

Articles related to Autoimmune Hepatitis:

(show top 50) (show all 2511)
# Title Authors Year
1
Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis. ( 30453094 )
2019
2
Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. ( 30484857 )
2019
3
Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine. ( 30502231 )
2019
4
Autoimmune hepatitis: Is the autoimmunity in the family? ( 30576081 )
2019
5
Association of CARD10 rs6000782 and TNF rs1799724 variants with paediatric-onset autoimmune hepatitis. ( 30581618 )
2019
6
Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. ( 30598587 )
2019
7
Pregnancy and Autoimmune Hepatitis: Presentation and Outcomes. ( 30616023 )
2019
8
Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. ( 30617453 )
2019
9
Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. ( 30619999 )
2019
10
Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. ( 30625402 )
2019
11
A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. ( 30650311 )
2019
12
Autoimmune hepatitis and complexities in management. ( 30651962 )
2019
13
Editorial: the role of vitamin D in autoimmune hepatitis. ( 30663100 )
2019
14
Editorial: the role of vitamin D in autoimmune hepatitis-authors' reply. ( 30663106 )
2019
15
Tryptophan-kynurenine profile in pediatric autoimmune hepatitis. ( 30666511 )
2019
16
Review article: stopping immunosuppressive treatment in autoimmune hepatitis (AIH): is it justified (and in whom and when)? ( 30667576 )
2019
17
Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. ( 30671977 )
2019
18
Adequacy of scoring systems in diagnosing paediatric autoimmune hepatitis: retrospective study using a control group children with Hepatitis B infection. ( 30703247 )
2019
19
Autoimmune hepatitis: Current and future therapeutic options. ( 30716203 )
2019
20
Steroid Free Treatment of Autoimmune Hepatitis in Selected Children. ( 30723013 )
2019
21
Risk of autoimmune hepatitis reactivation in patients with chronic hepatitis C and autoimmune hepatitis treated with direct-acting antivirals. ( 30758316 )
2019
22
Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. ( 30761563 )
2019
23
Depression: An Overlooked Villain in Autoimmune Hepatitis? ( 30773711 )
2019
24
Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis. ( 30802337 )
2019
25
What is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis? ( 30807845 )
2019
26
Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country. ( 30821090 )
2019
27
Focal Nodular Hyperplasia Mimicked Hepatocellular Carcinoma in an Autoimmune Hepatitis Patient With Regression of Cirrhosis. ( 30845888 )
2019
28
Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. ( 30850346 )
2019
29
Adoptive transfer of regulatory T cells stimulated by Allogeneic Hepatic Stellate Cells mitigates liver injury in mice with concanavalin A-induced autoimmune hepatitis. ( 30853178 )
2019
30
Secondary Hemophagocytic Lymphohistiocytosis: A Challenging Diagnosis in a Patient with Autoimmune Hepatitis. ( 30863647 )
2019
31
Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? ( 30868627 )
2019
32
Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? Authors' reply. ( 30868634 )
2019
33
Letter to Editor: Flare of Autoimmune Hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy. ( 30873620 )
2019
34
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. ( 30883091 )
2019
35
Are High-dose Steroids Really Necessary in Treatment of Autoimmune Hepatitis? ( 30885885 )
2019
36
A case of severe rhabdomyolysis associated with secondary adrenal insufficiency and autoimmune hepatitis. ( 30898957 )
2019
37
Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? ( 30900368 )
2019
38
Ductular reaction in acute onset autoimmune hepatitis. ( 30901095 )
2019
39
Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment-authors' reply. ( 30920035 )
2019
40
Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment. ( 30920038 )
2019
41
Development of autoimmune hepatitis after influenza vaccination; trigger or killer? ( 30926201 )
2019
42
Development and validation of a new simplified diagnostic scoring system for pediatric autoimmune hepatitis. ( 30928421 )
2019
43
Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. ( 30932290 )
2019
44
Liver Fibrosis Helps to Distinguish Autoimmune Hepatitis from DILI with Autoimmune Features: A Review of Twenty Cases. ( 30944815 )
2019
45
Autoimmune Hepatitis and Stellate Cells; an Insight into the Role of Autophagy. ( 30947648 )
2019
46
Expression and significance of Th17 cells and related factors in patients with autoimmune hepatitis. ( 30947662 )
2019
47
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. ( 30972807 )
2019
48
Steroid free treatment in autoimmune hepatitis: Is azathioprine monotherapy truly a viable option to obtain remission? ( 30982527 )
2019
49
Acute-onset Autoimmune Hepatitis in a Patient with Selective Immunoglobulin M Deficiency. ( 30996186 )
2019
50
Usefulness of CCR7- PD-1+ follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis. ( 31020718 )
2019

Variations for Autoimmune Hepatitis

Expression for Autoimmune Hepatitis

Search GEO for disease gene expression data for Autoimmune Hepatitis.

Pathways for Autoimmune Hepatitis

GO Terms for Autoimmune Hepatitis

Cellular components related to Autoimmune Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.76 F2 FAS FTCD GGT1 GPT HLA-A
2 external side of plasma membrane GO:0009897 9.62 CTLA4 F2 HLA-DRB1 PDCD1
3 MHC class II protein complex GO:0042613 9.26 HLA-DQB1 HLA-DRB1
4 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-A HLA-DQB1 HLA-DRB1
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-A HLA-DQB1 HLA-DRB1

Biological processes related to Autoimmune Hepatitis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 xenobiotic metabolic process GO:0006805 9.69 CYP1A2 CYP2D6 GGT1
2 interferon-gamma-mediated signaling pathway GO:0060333 9.65 HLA-A HLA-DQB1 HLA-DRB1
3 immune response GO:0006955 9.63 AIRE CTLA4 FAS HLA-A HLA-DQB1 HLA-DRB1
4 long-chain fatty acid biosynthetic process GO:0042759 9.54 CYP1A2 CYP2D6
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.52 HLA-DQB1 HLA-DRB1
6 antigen processing and presentation GO:0019882 9.5 HLA-A HLA-DQB1 HLA-DRB1
7 oxidative demethylation GO:0070989 9.49 CYP1A2 CYP2D6
8 heterocycle metabolic process GO:0046483 9.46 CYP1A2 CYP2D6
9 drug catabolic process GO:0042737 9.43 CYP1A2 CYP2D6
10 monoterpenoid metabolic process GO:0016098 9.4 CYP1A2 CYP2D6
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DQB1 HLA-DRB1
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.26 HLA-DQB1 HLA-DRB1
13 alkaloid metabolic process GO:0009820 8.96 CYP1A2 CYP2D6
14 drug metabolic process GO:0017144 8.8 CYP1A2 CYP2D6 TPMT

Molecular functions related to Autoimmune Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1
2 peptide antigen binding GO:0042605 8.8 HLA-A HLA-DQB1 HLA-DRB1

Sources for Autoimmune Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....